Kawaji Takahiro
Department of Ophthalmology, Faculty of Life Science, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.
Nippon Ganka Gakkai Zasshi. 2012 Nov;116(11):1046-51.
Ocular manifestations associated with transthyretin-related familial amyloidotic polyneuropathy (FAP), such as vitreous opacity and glaucoma, reportedly continue and worsen, even after liver transplantation, which should halt the progression of the neurological complications. We used panretinal laser photocoagulation, which damages the retinal pigment epithelium, the main synthetic source of amyloidogenic transthyretin in ocular tissues, to treat one eye each of two FAP patients as a pilot study. Panretinal laser photocoagulation prevented the progression of amyloid depositions in the vitreous and on the retinal surface in both cases during a 3 years follow-up. No serious complications occurred. Panretinal laser photocoagulation may be a safe and novel treatment option to mitigate ocular manifestations in FAP patients.
据报道，与转甲状腺素蛋白相关的家族性淀粉样多神经病（FAP）相关的眼部表现，如玻璃体混浊和青光眼，即使在肝移植后仍会持续并恶化，而肝移植本应阻止神经并发症的进展。我们进行了一项试点研究，对两名FAP患者的每只眼睛各进行了一次全视网膜激光光凝治疗，该治疗会损伤视网膜色素上皮，而视网膜色素上皮是眼组织中淀粉样转甲状腺素蛋白的主要合成来源。在3年的随访中，全视网膜激光光凝在两例患者中均阻止了玻璃体和视网膜表面淀粉样沉积物的进展。未发生严重并发症。全视网膜激光光凝可能是一种安全且新颖的治疗选择，可减轻FAP患者的眼部表现。
